Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.86 and last traded at C$0.87, with a volume of 254159 shares traded. The stock had previously closed at C$0.93.
Wall Street Analyst Weigh In
Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.
Check Out Our Latest Analysis on Oncolytics Biotech
Oncolytics Biotech Price Performance
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- How to trade using analyst ratings
- 3 Undervalued Stocks You Can Buy at a Discount Now
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- CD Calculator: Certificate of Deposit Calculator
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.